Ever Supreme Bio Tech released its 2025 financial results, reporting an EPS of NT$6.14. The company also announced that January 2026 revenue reached NT$58.2 million, maintaining steady YoY growth.

• Allogeneic CAR-T: The lead candidate CAR001 is in clinical trials for metastatic colorectal cancer (mCRC) and glioblastoma multiforme (GBM). Preliminary data shows tumor shrinkage of over 70% in certain cases, highlighting its potential for solid tumors.
• Exosome Platform: Subsidiary Shine Out Biotechnology developed the αDAT-EV platform, a world-first "active navigation" exosome capable of crossing the blood-brain barrier for targeted Parkinson’s disease therapy. The dEV-001 project completed its U.S. FDA Pre-IND meeting in January, with an IND filing pending.
• Outlook: With its AABB-accredited quality system, Ever Supreme is actively pursuing international out-licensing and CDMO opportunities as a "platform-based" regenerative medicine company.

Resource: 異體CAR-T、外泌體雙引擎推進 長聖去年每股賺6.14元